A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression (NCT07716098)
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[MDD\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).
Who can join: Review the eligibility criteria below.
Location: Anderson Clinical Research — Redlands, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Anderson Clinical Research — Redlands, California
- Psychiatric Medicine Associates LLC — Skokie, Illinois
- The Medical Research Network, LLC — New York, New York
- Kishiro Mental Clinic — Kawasaki,
- Tatsuta Clinic — Kobe,
- National Center of Neurology and Psychiatry — Kodaira-shi,
- Arata Clinic — Nagasaki,
- Hokkaido University Hospital — Sapporo,
- Sangenjaya neurology-psychosomatic clinic — Setagaya Ku,
- Maynds Tower Mental Clinic — Shibuya-ku,
- Tottori University Hospital — Tottori,
- Chung Shan Medical University Hospital — Taichung,
- Taipei Medical University — Taipei,
- Taipei Veterans General Hospital — Taipei,
- Linkou Chang Gung Memorial Hospital — Taoyuan,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depressive Disorder, Treatment-Resistant
- One-Day cTBS Over the Precuneus — Belmont, Massachusetts
- Intravenous Ketamine for Treatment-Resistant Depression — Rochester, Minnesota
- rTMS With and Without Text4Support for the Treatment of Resistant Depression. — Edmonton, Alberta
Explore by condition: All Depressive Disorder, Treatment-Resistant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.